Clinical Trial Update: A Study of Macitentan in Children Below 2 Years of Age [Phase 1]

View source ↗

Summary

A Phase 1 pediatric trial of macitentan for pulmonary arterial hypertension in children under 2 years old has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Macitentan (macitentan)

Snippet

Sponsor: Actelion | Conditions: Arterial Hypertension, Pulmonary | Phase 1 | Status: WITHDRAWN